Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 10/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044078 | 1.00 | PHGDH (0.46) | PHGDHCYP1A2CYP2C19SCDALDH1A1 | |
| SCHEMBL31029157 | 0.88 | MAPT (0.48) | PHGDHCYP1A2CYP2C19SCDINPPL1 | |
| SCHEMBL31043684 | 0.88 | MAPT (0.48) | PHGDHCYP1A2CYP2C19SCDINPPL1 | |
| SCHEMBL31043681 | 0.87 | PHGDH (0.44) | PHGDHCYP1A2CYP2C19SCDINPPL1 | |
| SCHEMBL31044020 | 0.87 | PHGDH (0.44) | PHGDHCYP1A2CYP2C19SCDSMN1; SMN2 | |
| SCHEMBL31029218 | 0.87 | PHGDH (0.44) | PHGDHCYP1A2CYP2C19SCDINPPL1 | |
| SCHEMBL31029072 | 0.87 | PHGDH (0.44) | PHGDHCYP1A2CYP2C19SCDSMN1; SMN2 | |
| SCHEMBL31044019 | 0.86 | SMN1; SMN2 (0.43) | PHGDHCYP1A2CYP2C19SCDALDH1A1 | |
| SCHEMBL31029111 | 0.83 | CYP1A2 (0.56) | CYP1A2CYP2C19ALDH1A1INPPL1SMN1; SMN2 | |
| SCHEMBL31044043 | 0.83 | CYP1A2 (0.56) | CYP1A2CYP2C19ALDH1A1INPPL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| WO-2024137981-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED (US) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | PHGDH 2045/4885CYP1A2 2623/4885CYP2C19 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.